Monitor regulatory approvals and closing timeline for the Labcorp transaction, which will transform OPKO into a pure-play biopharma company. The $125M royalty financing provides near-term liquidity but adds leverage. Watch for Q4 guidance on continuing operations and any updates on ModeX clinical data readouts in H1 2027.
Drugs in focus
OPK drug pipeline →mazdutide
● Neutral Named in this press release- Impact
- Phase
- Approved (China NMPA)
- Time to market
- Already approved and commercializing in China (June 2025 for weight management, September 2025 for type 2 diabetes). No US FDA filing has been announced; US approval is estimated in the 2027-2028 window if Eli Lilly initiates and completes global Phase 3 trials.
- Next catalyst
- None dated
What to watchWatch OPKO's quarterly royalty revenue from mazdutide as a gauge of China commercial uptake. Innovent's product revenue grew over 40% YoY in Q3 2026, but OPKO's specific royalty share is not separately disclosed. No near-term binary catalyst exists for this asset; the next potential catalyst would be Eli Lilly announcing a US Phase 3 program or FDA filing, which is not expected before 2027-2028.
Price Chart
Executive Summary
OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16% YoY), above the $136.6M consensus which included discontinued diagnostics revenue now reclassified. Net loss from continuing operations was $35.5M ($0.05 per share), versus consensus EPS of -$0.06. The headline event is the agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722M in cash at closing plus up to $150M in contingent consideration, and a $125M senior secured royalty financing with HealthCare Royalty.
Key Financial Metrics
Key Facts
- Continuing operations revenue $65.4M, +16% YoY from $56.4M
- Net loss from continuing operations $35.5M ($0.05 per share) vs consensus -$0.06
- Agreement to sell substantially all BioReference diagnostic operations to Labcorp for $722M cash at closing plus up to $150M contingent consideration
- $125M senior secured royalty financing with HealthCare Royalty tied to mazdutide royalty stream
- Guidance withdrawn for services revenue due to pending Labcorp transaction; product revenue guidance $164M-$169M for FY2026
- Cash, cash equivalents and restricted cash $403.2M at quarter end
- Repurchased 7,050,000 shares for ~$10.6M during the quarter
Financial Impact
Continuing ops revenue $65.4M (+16% YoY); net loss $35.5M; Labcorp deal $722M cash + $150M contingent; $125M royalty financing
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Global Products | $48.4M | +22.8% |
| Innovative Biotech | $17.0M | 0.0% |
Risk Factors
- Labcorp transaction may not close or may close on less favorable terms
- Continuing operations still unprofitable with operating loss of $31.4M
- R&D spending increasing ($30.4M in Q3 2026 vs $26.3M in Q3 2025) with no near-term revenue from pipeline
- Guidance withdrawn for services revenue creates uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395883 |
Track record
10 reports on OPK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $1.75 Now $1.62 −7.43% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 6/10 Viewing No price data
- Oct 15, 20264w ago 8-K Bullish 7/10 Entry $1.53 to $1.68 Now $1.62 +5.88% ▲ +9.80% +10.97% vs SPY
- Jul 27, 202616w ago 8-K Mixed 5/10 Entry $1.65 to $1.49 Now $1.62 −1.82% ▼ −9.70% −13.08% vs SPY
- Jul 23, 202616w ago Press Release Neutral 1/10 Entry $1.17 to $1.46 Now $1.62 +38.46% ▲ +24.79% +21.48% vs SPY
- Jun 15, 202622w ago Press Release Neutral 3/10 Entry $1.40 to $1.23 Now $1.62 +15.71% ▼ −12.14% −11.39% vs SPY
- May 15, 202626w ago DEFA14A Neutral 4/10 Entry $1.13 to $1.39 Now $1.62 +43.36% ▲ +23.01% +21.43% vs SPY
- Apr 30, 202628w ago Press Release Neutral 4/10 Entry $1.13 to $1.43 Now $1.62 +43.36% ▲ +26.55% +21.58% vs SPY
- Apr 22, 202629w ago Press Release Bullish 7/10 Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
- Apr 21, 202629w ago Press Release Neutral 1/10 Entry $1.23 to $1.15 Now $1.62 +31.71% ▼ −6.50% −9.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers